Skip to main content

6 Result(s)

within Wen-Jia Zuo Remove this filter

and

  1. Article

    Open Access

    Subty**-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial

    Triple-negative breast cancer (TNBC) is a heterogeneous disease and lacks effective treatment. Our previous study classified TNBCs into four subtypes with putative therapeutic targets. Here, we report the fina...

    Yin Liu, **u-Zhi Zhu, Yi **ao, Song-Yang Wu, Wen-Jia Zuo, Qiang Yu… in Cell Research (2023)

    Download PDF (1391 KB) View Article

  2. Article

    Open Access

    Molecular subty** and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial

    Triple-negative breast cancer (TNBC) is a highly heterogeneous disease, and molecular subty** may result in improved diagnostic precision and targeted therapies. Our previous study classified TNBCs into four...

    Yi-Zhou Jiang, Yin Liu, Yi **ao, **n Hu, Lin Jiang, Wen-Jia Zuo, Ding Ma… in Cell Research (2021)

    Download PDF (2169 KB) View Article

  3. No Access

    Article

    Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations

    Resistance to paclitaxel remains a major challenge in treating breast cancer. Our preclinical study suggested that TEKT4 germline variations in breast cancer are associated with paclitaxel resistance and increase...

    Yi-Zhou Jiang, Li-** Ge, ** **, Lei Fan, Min He… in Breast Cancer Research and Treatment (2021)

  4. No Access

    Article

    Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial

    This study was designed to determine the safety and clinical efficacy of metronomic chemotherapy combined with aromatase inhibitors (AIs) for hormone receptor (HR)-positive advanced breast cancer (ABC) patient...

    Jian-wei Li, Wen-jia Zuo, Diana Ivanova… in Breast Cancer Research and Treatment (2019)

  5. Article

    Open Access

    Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients

    Deregulation of the phosphoinositide 3-kinase (PI3K) pathway contributes to the development and progression of tumors. Here, we determine that somatic mutations in PIK3CA (44%), PIK3R1 (17%), AKT3 (15%), and PTEN

    Li Chen, Liu Yang, Ling Yao, **a-Ying Kuang, Wen-Jia Zuo, Shan Li… in Nature Communications (2018)

    Download PDF (3777 KB) View Article

  6. Article

    Open Access

    Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer

    Triple-negative breast cancer (TNBC) is a highly heterogeneous group of cancers, and molecular subty** is necessary to better identify molecular-based therapies. While some classifiers have been established,...

    Yi-Rong Liu, Yi-Zhou Jiang, **ao-En Xu, Ke-Da Yu, ** **, **n Hu… in Breast Cancer Research (2016)

    Download PDF (2755 KB) View Article